[Rinsho ketsueki] The Japanese journal of clinical hematology最新文献_第9页

[An enjoyable 23-year career as a hematologist in metropolitan emergency hospitals, a researcher of post-transplant survivorship, and a community hematologist-oncologist]. [23年愉快的职业生涯，在大都会急救医院做血液科医生，研究移植后存活，社区血液科肿瘤学家]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.803

Saiko Kurosawa

{"title":"[An enjoyable 23-year career as a hematologist in metropolitan emergency hospitals, a researcher of post-transplant survivorship, and a community hematologist-oncologist].","authors":"Saiko Kurosawa","doi":"10.11406/rinketsu.64.803","DOIUrl":"https://doi.org/10.11406/rinketsu.64.803","url":null,"abstract":"I would like to express my sincere gratitude to be given such an honorable opportunity. I am more than happy to share my personal experience as one example of the diversity of women in hematology. After graduating from Tohoku University, I began my residency training at Japanese Red Cross Musashino Hospital and Tokyo Metropolitan Bokutoh Hospital, which are extremely busy designated hospitals in Tokyo. Both had highly active emergency care centers, and I believe that the rigorous training I received there not only honed my basic patient care skills, but also increased my physical and mental strength. Since I referred many patients to National Cancer Center Hospital, I found it amusing that Dr. Fukuda recruited me based on the recommendation of those patients. I was so fortunate to have many opportunities to contribute as a primary investigator in meaningful nationwide clinical studies. At present, I appreciate my country life as a community hematologist-oncologist. I also did not expect that I would have continuing opportunities to collaborate with researchers nationwide thanks to rapid progress in remote communications, and nothing would make me happier than to continue participating in projects on cancer survivorship.","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 8","pages":"803-809"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10183274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Risk assessment and prophylactic treatment strategies for central nervous system relapse of diffuse large B-cell lymphoma]. 弥漫性大b细胞淋巴瘤中枢神经系统复发的风险评估及预防治疗策略。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.490

Kana Miyazaki

引用次数: 0

[Posttransplant complications: GVHD and SOS/VOD]. [移植后并发症:GVHD和SOS/VOD]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.524

Yasuo Mori

{"title":"[Posttransplant complications: GVHD and SOS/VOD].","authors":"Yasuo Mori","doi":"10.11406/rinketsu.64.524","DOIUrl":"https://doi.org/10.11406/rinketsu.64.524","url":null,"abstract":"Several novel agents (e.g., molecularly targeted drug, bispecific antibody, antibody-drug conjugate, chimeric antigen receptor T-cell therapy) have successively emerged in clinical practice and are occasionally used in allogeneic hematopoietic cell transplantation (allo-HCT) settings. These drugs are expected to reduce pretransplant tumors, lower the risk of relapse with posttransplant maintenance therapy, and consequently improve transplant outcomes. Additionally, some molecularly targeted drugs could be adapted to treat steroid-refractory acute and/or chronic graft-versus-host disease (GVHD), which remained the leading cause of nonrelapse mortality after allo-HCT. However, these agents develop an excessive immune reaction, including GVHD, or presented an increased risk of sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD) as their \"off-target\" effects. Thus, this review aimed to summarize the risk assessment and management of post-posttransplant complications, focusing on GVHD and SOS/VOD, in the era of molecularly targeted therapy. Moreover, recent advances in GVHD or SOS/VOD prophylaxis and treatment using novel agents/devices are also discussed.","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 6","pages":"524-532"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9803681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Effective therapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy with obinutuzumab for follicular lymphoma in leukemic phase]. [环磷酰胺、阿霉素、长春新碱和强的松龙联合比努单抗化疗对白血病期滤泡性淋巴瘤的有效治疗]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.119

Satoko Osanai, Shoko Oshima, Satoru Itoi, Yutaka Kato, Michiko Ryuzaki, Yuki Izuka, Norina Tanaka, Midori Ishiyama, Akihito Shinohara, Kentaro Yoshinaga, Masayuki Shiseki, Hiromi Onizuka, Yoji Nagashima, Junji Tanaka

{"title":"[Effective therapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy with obinutuzumab for follicular lymphoma in leukemic phase].","authors":"Satoko Osanai, Shoko Oshima, Satoru Itoi, Yutaka Kato, Michiko Ryuzaki, Yuki Izuka, Norina Tanaka, Midori Ishiyama, Akihito Shinohara, Kentaro Yoshinaga, Masayuki Shiseki, Hiromi Onizuka, Yoji Nagashima, Junji Tanaka","doi":"10.11406/rinketsu.64.119","DOIUrl":"https://doi.org/10.11406/rinketsu.64.119","url":null,"abstract":"The patient, a 56-year-old lady, also exhibited numerous lymphadenopathy, hepatosplenomegaly, hyperleukocytosis (167,200/µl, aberrant lymphocytes 91.5%), and fever. A lymph node biopsy revealed follicular lymphoma (FL), grade 1. Peripheral blood tumor cells did not express CD10, which was a distinctive characteristic of the lymph node specimen. To prevent tumor lysis syndrome (TLI), CHOP was delivered without an anti-CD20 antibody, but afterward, residual lymphoma cells were found in peripheral blood (>80%). As a result, obinutuzumab (Obi) was given on day 8 following the second round of CHOP, and the tumor cells in the peripheral blood vanished without any major side effects like TLI. She underwent six chemotherapy sessions before receiving maintenance therapy with Obi and achieving a full metabolic response. According to reports, leukemic FL exhibits negative CD10 expression in peripheral blood lymphoma cells, while leukemic mantle cell lymphoma also shows this trait. Therefore, it is important not to confuse the two types in diagnosis. Leukemic FL with significant leukocytosis is reportedly uncommon and has a bad prognosis. Our case indicates that CHOP with Obi would be a good alternative for cases like yours, however, there have been a few cases recorded. Further case accumulation or investigation is warranted.","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 2","pages":"119-124"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9220911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.234

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.293

引用次数: 0

[Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria]. [日本患者对治疗阵发性夜间血红蛋白尿的ravulizumab和eculizumab的偏好]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.9

Ken Ishiyama, Kensuke Usuki, Takayuki Ikezoe, Akihiko Gotoh, Karl-Johan Myren, Ioannis Tomazos, Akihiko Shimono, Haruhiko Ninomiya, Masatoshi Sakurai, Shinji Nakao, Jun-Ichi Nishimura

{"title":"[Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria].","authors":"Ken Ishiyama, Kensuke Usuki, Takayuki Ikezoe, Akihiko Gotoh, Karl-Johan Myren, Ioannis Tomazos, Akihiko Shimono, Haruhiko Ninomiya, Masatoshi Sakurai, Shinji Nakao, Jun-Ichi Nishimura","doi":"10.11406/rinketsu.64.9","DOIUrl":"https://doi.org/10.11406/rinketsu.64.9","url":null,"abstract":"Ravulizumab is the first long-acting complement inhibitor approved for paroxysmal nocturnal hemoglobinuria (PNH) treatment. We evaluated patient preference for ravulizumab or eculizumab among Japanese adults with PNH. The ALXN1210-PNH-301 (NCT02946463) and ALXN1210-PNH-302 (NCT03056040) studies included 23 Japanese adults who are enrolled in complement inhibitor treatment-naive and eculizumab (≥6 months) treatment. Patient preference was assessed using the PNH-specific patient preference questionnaire (PNH-PPQ©). Most patients preferred ravulizumab (19/23, 82.6%), none preferred eculizumab, and four (17.4%) reported no preference (χ2 test, p<0.005). The preference for ravulizumab was driven by its lower infusion frequency (every 8 weeks) compared with eculizumab (every 2 weeks). The included Japanese patients with PNH preferred ravulizumab because of its reduced infusion frequency, which increases activity planning ability, treatment convenience, and overall quality of life, as compared with eculizumab. These data provide useful insight into patient perspectives and may aid decision-making for PNH treatment.","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 1","pages":"9-17"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10712100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Warm autoimmune hemolytic anemia complicated with pulmonary hypertension exhibiting pulmonary mosaic attenuation pattern]. 温性自身免疫性溶血性贫血合并肺动脉高压表现为肺马赛克衰减模式。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.290

Fumito Arima

引用次数: 0

[Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma]. [弥漫性大b细胞淋巴瘤的细胞动力学和tisagenleclear的预后]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.167

Ryo Hanajiri, Katsuya Furukawa, Marie Nakashima, Yoko Ushijima, Kazuyuki Shimada, Yuichi Ishikawa, Seitaro Terakura, Makoto Murata, Hitoshi Kiyoi

{"title":"[Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma].","authors":"Ryo Hanajiri, Katsuya Furukawa, Marie Nakashima, Yoko Ushijima, Kazuyuki Shimada, Yuichi Ishikawa, Seitaro Terakura, Makoto Murata, Hitoshi Kiyoi","doi":"10.11406/rinketsu.64.167","DOIUrl":"https://doi.org/10.11406/rinketsu.64.167","url":null,"abstract":"CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy has shown promise as treatment of relapsed or refractory B-cell malignancies. However, the clinical utility of early CAR-T monitoring within 1 month after infusion has not been elucidated. In this study, we quantitatively measured CAR-T kinetics in peripheral blood on days 2, 4, 7, 9, 11, 14, 21, and 28 post-infusion using flow cytometry and quantitative polymerase chain reaction in 13 patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) treated with tisagenlecleucel (tisa-cel). No relationships were identified between bulk CAR-T kinetics and treatment outcomes. Interestingly, the magnitude of CD4+ CAR-T expansion was higher in responders than in nonresponders, while CD8+ CAR-T expansion was minimal in responders. Additionally, CAR-T proliferation was more pronounced in patients with cytokine release syndrome. Our results suggest that CD4+ CAR-T cellular kinetics within 1 month after CAR-T infusion may predict its efficacy after tisa-cel therapy in adult patients with DLBCL.","PeriodicalId":6352,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"64 3","pages":"167-174"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9612094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2023-01-01 DOI: 10.11406/rinketsu.64.437

引用次数: 0